Publisher Correction: Truncated FGFR2 is a clinically actionable oncogene in multiple cancers

  • Daniel Zingg
  • , Jinhyuk Bhin
  • , Julia Yemelyanenko
  • , Sjors M Kas
  • , Frank Rolfs
  • , Catrin Lutz
  • , Jessica K Lee
  • , Sjoerd Klarenbeek
  • , Ian M Silverman
  • , Stefano Annunziato
  • , Chang S Chan
  • , Sander R Piersma
  • , Timo Eijkman
  • , Madelon Badoux
  • , Ewa Gogola
  • , Bjørn Siteur
  • , Justin Sprengers
  • , Bim de Klein
  • , Richard R de Goeij-de Haas
  • , Gregory M Riedlinger
  • Hua Ke, Russell Madison, Anne Paulien Drenth, Eline van der Burg, Eva Schut, Linda Henneman, Martine H van Miltenburg, Natalie Proost, Huiling Zhen, Ellen Wientjens, Roebi de Bruijn, Julian R de Ruiter, Ute Boon, Renske de Korte-Grimmerink, Bastiaan van Gerwen, Luis Féliz, Ghassan K Abou-Alfa, Jeffrey S Ross, Marieke van de Ven, Sven Rottenberg, Edwin Cuppen, Anne Vaslin Chessex, Siraj M Ali, Timothy C Burn, Connie R Jimenez, Shridar Ganesan, Lodewyk F A Wessels, Jos Jonkers

Research output: Contribution to journalComment/Letter to the editorAcademicpeer-review

6 Downloads (Pure)

Abstract

Correction to: Nature https://doi.org/10.1038/s41586-022-05066-5 Published online 10 August 2022

Original languageEnglish
Pages (from-to)E13-E13
JournalNature
Volume609
Issue number7929
Early online date1 Sept 2022
DOIs
Publication statusPublished - 29 Sept 2022

Fingerprint

Dive into the research topics of 'Publisher Correction: Truncated FGFR2 is a clinically actionable oncogene in multiple cancers'. Together they form a unique fingerprint.

Cite this